Immune system study for advanced prostate cancer
Part of Cancer clinical trials.
This study looks at how the immune system reacts to advanced prostate cancer that has spread to other parts of the body. Researchers will use special techniques to analyze tissue samples, hoping to find new ways to treat this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man over 18 and under 85 years old.
- You must have a confirmed diagnosis of prostate adenocarcinoma, ductal adenocarcinoma, or intraductal carcinoma.
- Your cancer must have spread to other parts of the body (confirmed by imaging).
- You must not have had any prior treatment for your prostate cancer, such as hormone therapy (ADT) or other systemic treatments.
- You must be in generally good health (ECOG 0-2) and have a life expectancy of more than 6 months.
- Your blood counts and organ function must be within acceptable levels (e.g., hemoglobin, white blood cells, liver and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to predict how well hormone therapy combined with newer drugs works for men with prostate cancer that has spread. It uses advanced tissue analysis to help tailor treatment.
This study tests a new form of abiraterone (a hormone therapy) against the standard one in men whose prostate cancer has spread and no longer responds to usual hormone treatment. Participants must have had limited prior treatments and be in decent overall health.
This study tests adding a targeted local treatment (like radiation or surgery) to standard hormone therapy for men with advanced prostate cancer that still shows up on a special scan. The goal is to see if this combination helps control the cancer better.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This study is comparing two drugs, abiraterone and darolutamide, to see how well they work for advanced prostate cancer. You might join if your cancer has spread and your doctor agrees these treatments could help.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
Hear when a new Metastatic Hormone-Sensitive Prostate Cance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.